CSIMarket Company Name, Ticker, Customers, else..
 
Biodesix Inc   (NASDAQ: BDSX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $27.1900 $1.01 3.858%
Day's High: $27.899999618530273 Week Perf: 8.46 %
Day's Low: $ 25.89 30 Day Perf: 15.7 %
Volume (M): 45,033 52 Wk High: $ 31.31
Volume (M$): $ 0 52 Wk Avg: $13.52
Open: $25.97 52 Wk Low: $5.26



 Market Capitalization (Millions $) 263
 Shares Outstanding (Millions) 10
 Employees 334
 Revenues (TTM) (Millions $) 96
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Business Description


Biodesix Inc is a molecular diagnostics company that specializes in the development and commercialization of diagnostic tests for various diseases, including cancer. The company focuses on personalized medicine, aiming to provide physicians with actionable information that can help in making treatment decisions for their patients. Biodesix offers a range of tests that utilize advanced technology platforms to analyze genetic and proteomic biomarkers with the goal of improving patient outcomes. Their innovative diagnostic tests are designed to enable early disease detection, treatment monitoring, and prediction of disease progression.


   Company Address: 919 West Dillon Rd Louisville 80027 CO
   Company Phone Number: 417-0500   Stock Exchange / Ticker: NASDAQ BDSX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GH        1.6% 
NTRA        0.81% 
PSNL        0.36% 
VCYT   -1.66%    
PMVP        10.33% 
THRY        7.07% 
• View Complete Report
   



Clinical Study

Advancements in Biomarker-Based Predictions for Non-Small Cell Lung Cancer Survival Biodesix’s VeriStrat Test

Published Fri, May 23 2025 11:18 AM UTC

At the 2025 ASCO Annual Meeting, Biodesix announced significant discoveries from their INSIGHT study, emphasizing the predictive capabilities of the VeriStrat Host Immune Classifier (HIC) in assessing overall survival outcomes for patients with non-small cell lung cancer (NSCLC) treated with immunotherapies. This article provides a overview of the study s findings and their...
Business Update

Biodesix Breaks Ground at CHEST 2024, Yet Faces Market Headwinds

Published Mon, Oct 7 2024 10:47 AM UTC

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study In a bold maneuver that showcases its commitment to advancing lung disease diagnostics, Biodesix, Inc. (Nasdaq: BDSX) is set to make waves at the highly anticipated CHEST Annual Meeting 2024 in Boston, Massachusetts. On Tuesday, October 8, at 10:20 am ET, th...
Business Update

Revamping Lung Disease Diagnosis: Biodesix Unveils Promising Breakthrough at ATS 2024 Annual Meeting

Published Tue, May 21 2024 10:47 AM UTC

Biodesix, Inc. (Nasdaq: BDSX), a pioneering diagnostic solutions company specializing in lung disease, has recently announced ground-breaking new data that will be presented at the 2024 American Thoracic Society (ATS) International Conference. The data will demonstrate the success of Biodesix s Nodify XL2 Test in accurately stratifying lung nodule risk in patients with and w...
Business Update

Biodesix's Lung Diagnostic Testing Powers Impressive Revenue and Volume Growth in Q1 2024, Reinforcing Commitment to Patients' Well-being.

Published Thu, May 9 2024 2:24 AM UTC

Biodesix Announces Impressive First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule ManagementLOUISVILLE, Colo. - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company specializing in lung disease, has reported its financial and operating results for the first quarter ended March 31, 2024. The company s performance during this...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.73
Price to Sales (Expected) -
Price to Book 28.75
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.76
Working Capital Ratio 2.82
Leverage Ratio (MRQ) 9.36
Total Debt to Equity 5.09
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.1 $
Revenues (TTM) 9.95 $
Cash Flow (TTM) 0.83 $
Cash 2.65 $
Book Value 0.95 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 287,713
Net Income per Employee (TTM) -95,680
Receivable Turnover Ratio (TTM) 9.94
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 1.08

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -24.27 %
Net Margin (MRQ) -30.5 %
Net Cash Flow Margin (MRQ) 25.77 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Biodesix Inc's Segments
Diagnostic Tests    87.23 % of total Revenue
Development Services    12.77 % of total Revenue

  Biodesix Inc Outlook

On January 10 2025 the Biodesix Inc provided following guidance

Biodesix Inc. has recently announced its preliminary financial results for the fourth quarter and the entirety of 2024, emphasizing significant growth in revenue. According to the provided financial guidance, the company anticipates generating approximately $71.3 million in revenue for the full year of 2024. This figure marks a remarkable increase of 45% compared to the previous year.

The impressive growth in revenue underscores Biodesix's ongoing commitment to expanding its market presence and enhancing its product offerings. This substantial rise not only indicates the company's successful strategies in driving sales but also reflects the increasing demand for its innovative solutions in the diagn...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.